Clinical Trials

8 enrolled

Prostatic Neoplasms

NCT06216249 2026-03-10

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

90 enrolled

Prostatic Neoplasms

NCT06330805 2026-03-09

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

70 enrolled

Phase NA Active not recruiting

Prostatic Neoplasms

NCT03085043 2026-03-05

Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate Cancer

98 enrolled

Prostatic Neoplasms

NCT06632977 2026-03-04

PREDICT

474 enrolled

Prostatic Neoplasms

NCT06675357 2026-03-04

Using FAPI PET/MRI to Evaluate Prostate Cancer

30 enrolled

Prostatic Neoplasms

NCT06931340 2026-03-04

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

1,260 enrolled

Prostatic Neoplasms

NCT07000084 2026-03-04

GAIN-BCG

330 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05676463 2026-03-03

MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer

Phase 2 Terminated

6 enrolled

Prostatic Neoplasms

NCT07128680 2026-02-27

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

Phase 1 Recruiting

33 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04258462 2026-02-23

Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors

54 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04006522 2026-02-20

89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

55 enrolled

Carcinoma, Renal Cell

NCT06526299 2026-02-20

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

51 enrolled

Prostatic Neoplasms

NCT06305598 2026-02-19

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1 Recruiting

14 enrolled

Prostatic Neoplasms

NCT03933670 2026-02-18

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

60 enrolled

Prostatic Neoplasms

NCT05641935 2026-02-17

Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation

210 enrolled

Carcinoma, Renal Cell

NCT06236139 2026-02-17

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

48 enrolled

Prostatic Neoplasms

NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Phase 4 Recruiting

75 enrolled

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT06625034 2026-02-10

Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer

108 enrolled

Prostatic Neoplasms

NCT06733350 2026-02-09

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

Phase 4 Suspended

600 enrolled

Prostatic Neoplasms

NCT05730712 2026-02-06

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

7 enrolled

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT04459273 2026-02-05

FAPI PET RDRC

26 enrolled

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther hematologic neoplasm

Adrenal Gland Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Unknown Primary, Skin Neoplasms, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Hematologic Neoplasms

NCT07276438 2026-02-05

Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial

Phase NA Recruiting

186 enrolled

Prostatic Neoplasms

NCT06636526 2026-02-04

The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study).

Recruiting

1,000 enrolled

Genetic Risk Score, Prostatic Neoplasms, Genetic Predisposition to Disease

NCT05946213 2026-02-02

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

1,209 enrolled

Prostatic Neoplasms

NCT07097142 2026-02-02

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

486 enrolled

Urinary Bladder Neoplasms

NCT04989946 2026-01-28

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Phase 1/2 Recruiting

60 enrolled

Prostatic Neoplasms

NCT06145633 2026-01-28

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

15 enrolled

Prostatic Neoplasms

NCT07219147 2026-01-28

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 1 Recruiting

30 enrolled

Prostatic Neoplasms

NCT06205316 2026-01-20

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

118 enrolled

Prostatic Neoplasms

NCT04134260 2026-01-14

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

586 enrolled

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04513717 2026-01-14

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

2,753 enrolled

Prostatic Neoplasms

NCT05053152 2026-01-14

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

194 enrolled

Prostatic Neoplasms

NCT05327686 2026-01-14

SAMURAI

240 enrolled

Carcinoma, Renal Cell

NCT06039371 2026-01-14

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

69 enrolled

Prostatic Neoplasms

NCT06500455 2026-01-14

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

BreastCNSDermatologicGenitourinaryThoracic

269 enrolled

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT04777071 2026-01-09

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

141 enrolled

Prostatic Neoplasms

NCT05689021 2026-01-07

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

8 enrolled

Prostatic Neoplasms

NCT05830058 2026-01-05

Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

DermatologicGenitourinaryThoracic

32 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT06384222 2025-12-30

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

32 enrolled

CNSEndocrineGenitourinaryNET

Prostatic Neoplasms

NCT06788886 2025-12-30

Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases

Phase NA Recruiting

147 enrolled

Brain Neoplasms, Multiple Sclerosis, Prostatic Neoplasms, Neuroendocrine Tumors

NCT06378866 2025-12-26

DIVINE

532 enrolled